Key result
A higher baseline splenic volume index was independently associated with an increased risk of 2-year cardiac death or heart failure readmission after TAVR (HR 1.09 per 10 mL/m2 increase).
Why the study?
Although splenic size has been proposed as a prognostic factor in heart failure cohorts, its clinical implication in patients receiving TAVR remains unknown.
Does baseline indexed splenic volume predict 2-year cardiac death or heart failure readmission in patients undergoing trans-catheter aortic valve replacement?
Cohort (n=343)
No
Does baseline indexed splenic volume predict 2-year cardiac death or heart failure readmission in patients undergoing trans-catheter aortic valve replacement?
Hazard Ratio: 1.09 (95% CI 1.01–1.18)
Absolute Event Rate: 10% vs 4%
p-value: p=0.041
A higher baseline indexed splenic volume is associated with an increased risk of cardiac death or heart failure readmission at 2 years following trans-catheter aortic valve replacement.
May aid post-TAVR risk stratification; hypothesis-generating and requires validation before clinical use.
Background: The spleen seems to be a significant buffer of the effective circulating blood volume by changing its size dramatically according to hemodynamics. The cardio–splenic relationship has been recently proposed in the literature regarding heart failure cohorts, and the splenic size has been proposed as a prognostic factor in these cohorts. However, the clinical implication of the splenic size in patients receiving trans-catheter aortic valve replacement (TAVR) remains unknown. Methods: Patients who underwent TAVR at our institute between 2015 and 2022 were eligible. Of these, the patients whose abdominal computed tomography imaging was obtained before TAVR were included. The volume of the spleen was measured in all the participants. The prognostic impact of the indexed splenic volume (SVI) on the 2-year cardiac death or heart failure readmissions was evaluated. Results: A total of 343 patients (86 years, 98 males) were included. The median value of the peak velocity at the aortic valve was 4.4 (4.0, 4.8) m/s and the median SVI was 65.5 (48.9, 86.9) mL/m2. A lower SVI tended to be associated with a lower cardiac output, whereas a higher SVI was associated with a higher plasma volume. The SVI was independently associated with the 2-year cardiac death or heart failure readmission after TAVR with a hazard ratio of 1.09 (95% confidence interval 1.01–1.18, p = 0.041), adjusted for potential confounders. A calculated cutoff of SVI was 70.2 mL/m2, which significantly stratified the cumulative incidence of the primary outcome (10% versus 4%, p = 0.033). Conclusion: A high baseline SVI, which was associated with systemic congestion, was associated with a higher incidence of cardiac death or heart failure readmission after TAVR. Further studies are warranted to clarify the detailed cardio–splenic relationship and implication of measuring the SVI in this cohort.
No takes yet. Share an insight, caveat, or question.
Imamura et al. (2023) conducted a cohort in Severe aortic stenosis (n=343). High baseline splenic volume index (SVI) vs. Low baseline splenic volume index was evaluated on 2-year cardiac death or heart failure readmission (HR 1.09, 95% CI 1.01-1.18, p=0.041). A higher baseline splenic volume index was independently associated with an increased risk of 2-year cardiac death or heart failure readmission after TAVR (HR 1.09 per 10 mL/m2 increase).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: